Tomáš Büchler
A5086971449- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Testicular diseases and treatments
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Glycosylation and Glycoproteins Research
- Economic and Financial Impacts of Cancer
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- Urinary and Genital Oncology Studies
Charles University
2016-2025
Thomayer University Hospital
2016-2025
University Hospital in Motol
2023-2025
Queen Mary University of London
2024
University of Sheffield
2024
Barts Health NHS Trust
2024
Sheffield Teaching Hospitals NHS Foundation Trust
2024
Merck (Japan)
2020
Roche (Switzerland)
2020
AstraZeneca (Brazil)
2020
The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared placebo after surgery in patients clear cell renal carcinoma at an increased risk recurrence. reported here, additional 6 months follow-up, was designed to assess longer-term efficacy and safety versus placebo, as well secondary exploratory endpoints.In multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, adults aged 18 years or older recurrence...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes.
<h3>Importance</h3> DCVAC/PCa is an active cellular immunotherapy designed to initiate immune response against prostate cancer. <h3>Objective</h3> To evaluate the efficacy and safety of plus chemotherapy followed by maintenance treatment in patients with metastatic castration-resistant cancer (mCRPC). <h3>Design, Setting, Participants</h3> The VIABLE double-blind, parallel-group, placebo-controlled, phase 3 randomized clinical trial enrolled mCRPC among 177 hospital clinics US Europe between...
Interferon (IFN) signaling has been suggested to play an important role in colorectal carcinogenesis. Our study aimed examine potentially functional genetic variants interferon regulatory factor 3 (IRF3), IRF5, IRF7, type I and II IFN their receptor genes with respect cancer (CRC) risk clinical outcome. Altogether 74 single nucleotide polymorphisms (SNPs) were covered by the 34 SNPs genotyped a hospital-based case-control of 1327 CRC cases 758 healthy controls from Czech Republic. We also...
Background:The Czech Republic ranks among the countries with highest cancer burden in Europe as well worldwide.The purpose of this study is to summarize long-term trends and provide up-to-date estimates incidence mortality rates after 2011.Data Methods: The National Cancer Registry (CNCR) was instituted 1977 contains information collected over a 34-year period standardized registration covering 100% dia gnoses within entire population.The CNCR analysis supported by demographic data Death...
Introduction The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid have been associated disease success. This subsequent analysis explores outcomes in or without specific prognostic features. Methods In CLEAR, clear RCC were randomly...
Colorectal cancer (CRC) is one of the most frequently diagnosed malignancies worldwide. It routinely cured by a 5-fluorouracil (5-FU)-based chemotherapy which improves outcomes in patients. We investigated effect single nucleotide polymorphisms (SNPs) two microRNA (miRNA)-encoding genes that have been previously reported as important prognosis patients with stage III CRC and treated 5-FU-based chemotherapy. Two SNPs (rs4919510 miR-608 rs213210 miR-219-1) were genotyped 1083 recruited Czech...
There is increasing evidence indicating a role for Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) development and prognosis. This study evaluated F. as prognostic biomarker, by assessing its association with post-diagnosis survival from CRC. From September 2008 to April 2012 CRC patients (n = 190) were recruited three hospitals within the Czech Republic. DNA copies measured adjacent non-malignant tumor tissues using quantitative real-time PCR. Cox Proportional Hazards (HR)...
About 20% of patients with renal cell carcinoma present non-clear histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role cytoreductive nephrectomy (CN) in metastatic nccRCC is contentious. Limited data exist on CN under current standard care. This retrospective study focused impact upfront outcomes first-line immune checkpoint inhibitor (IO) combinations or tyrosine kinase (TKI) monotherapy. The included 221 and...
252 Background: Liquid biopsy assays in mCRPC are utilized for treatment eligibility of PARP inhibitors (HRR) and Pembrolizumab (MSI High). These ctDNA targeted gene panels provide translational data beyond mutations. Tumor Fraction (TF), the percentage cfDNA from tumor, is a promising prognostic efficacy biomarker pre-chemo mCRPC, potential predictive to post-chemo PSMA radioligand therapy. Methods: We analyzed run with Illumina-TSO500 CA209-7DX Ph3 trial (Nivo+chemo vs. Chemo chemo-naïve...
693 Background: Platinum-based chemotherapy followed by avelumab 1L maintenance treatment for patients with nonprogressive disease is a standard of care in la/mUC. In the Czech Republic, following EU approval, there requirement to provide real-world data “highly innovative medicinal products” and obtaining reimbursement requires registry creation collection. Interim results from retrospective analysis national Republic were reported previously; here, we report longer-term results. Methods:...
Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated association antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin insulin patient outcomes validated prognostic role a drug score in mUC patients treated enfortumab vedotin (EV) monotherapy. Data from 436 enrolled ARON-2EV retrospective were analyzed according to medications...
Abstract In patients with testicular germ cell tumours (TGCT), sperm cryopreservation prior to anti-cancer treatment represents the main fertility preservation approach. However, it is associated low recovery rate after thawing. Since a high-energy demanding cell, which supplied by glycolysis and oxidative phosphorylation (OXPHOS), mitochondrial dysfunctionality can directly result in anomalies. this study, we investigated bioenergetic pattern of cryopreserved TGCT comparison normozoospermic...